Edward B. Garon relates to anticancer vaccines, an area full of promises for lung cancer patients, their potential caveats compared to other novel treatment approaches, depicts the most interesting trial results from the phase I trial of intratumoral administration of CCL21-gene modified dendritic cells combined with intravenous pembrolizumab for advanced NSCLC and explains how antibody drug conjugates like datopotamab deruxtecan, a novel TROP2-directed ADC, fit in the therapeutic landscape in the future.

Here is the full ESMO 2021 Lung Cancer report.